8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Bristol Myers Squibb raises 2026 revenue outlook after third-quarter growth
Filed with the SEC on · Summarized by InvestorsBot
Bristol Myers Squibb reported third-quarter 2026 revenue of $13.1 billion, up 7% from a year earlier, while Growth Portfolio revenue rose 12% to $7.7 billion; GAAP EPS was $1.05 and non-GAAP EPS was $1.35, including a $0.58 per-share net impact from acquired IPRD charges and licensing income. On October 29, 2026, the company raised its full-year revenue guidance to $49.75 billion-$50.25 billion from $49.0 billion-$50.0 billion, but lowered its non-GAAP EPS outlook to $6.35-$6.55 from $6.75-$7.00, reflecting a $0.60 per-share impact from those charges and licensing income.